Please login to the form below

Let's be ambitious for patients and life sciences investment in Global Britain

“Take up of new medicines in the UK continues to be slow by international standards”. Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals. All have promised to accelerate access of new medicines to patients. Sadly, 12 years on, the 2017 Life Sciences Industrial Strategy could only restate the challenge: “Evidence demonstrates that access to and diffusion of products in the NHS is often slower than in some comparable countries”. Can we ever break this cycle? By Andrew Harrison, Group Managing Director of Hanover Health.

The Government’s 2019 election manifesto pledged to make the UK the leading hub for life sciences. Yet with the sector seen as crucial to economic regeneration post-Brexit and post-pandemic, the slower use of innovative medicines in the UK is a drag anchor on the Government’s ambitions. It is repeatedly acknowledged by global industry headquarters to be a negative factor when considering investment location decisions. And whilst the UK still does well for investment, it could do much better.

In post-Brexit ‘Global Britain’, Government wants a rejuvenated MHRA to help the UK become a global early launch market. But the UK also needs an HTA system fit for the future. Companies are unlikely to flock to the UK for an early licence unless there is also early access and use in the NHS.

From the Cancer Drugs Fund to the promised Innovation Drugs Fund, initiatives have been created as technical ‘work-arounds’ for NICE and for an HTA system that has not kept pace with the types of treatments now being developed. These initiatives have enabled some patient access and are welcome, but their very existence highlights the ongoing absence of substantive reform to NICE itself.

The current NICE Methods Review is an opportunity that should be grasped by Government to enhance patient access to new medicines and simultaneously boost the attractiveness of the UK to the life sciences industry.

Global boardrooms that control huge and internationally mobile investment budgets have welcomed the Government’s positive rhetoric towards life sciences. But actions speak louder than words and limited NICE reform will be seen as a conscious act of apathy by the UK Government towards the industry.

One argument against NICE reform is its potential greater impact on NHS budgets.

Industry argues that the remarkable VPAS deal which caps NHS spending on medicines would cover any costs. However, many in NHSE and DHSC argue that the VPAS is not a true financial safety net as reimbursement decisions taken now will have expenditure consequences after the current scheme ends in 2023.

Perhaps it is time to consider a new more ambitious deal which works for Government, patients and industry? A new 10-year VPAS with more substantial and defined NICE reform locked in?

A similar scheme capping NHS medicines spend would give long term (and much needed) certainty and security to NHS finances and a longer time-horizon would remove the Government’s end-of-deal-risk on reimbursement decisions. As well as NICE reform, industry could seek Government commitments to curtail NHS England’s cost-squeezing tenders which create no actual saving to the NHS or taxpayer - because medicine spend is already capped - but which damage UK reputation as anti-innovation in the eyes of global pharma headquarters.

A triple win is on offer. Patients gain faster and fuller access to the latest medicines; the UK is seen as more attractive and innovation-friendly by investing industry headquarters; and the NHS and Treasury gain this without paying a penny more than planned due to capped medicines spend until 2034.

For both Government and industry here is an opportunity to break the cycle of unfilled ambitions on patient access to the latest medicines, and to remove an important barrier to life sciences investment for the new Global Britain.

9th November 2020

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

Addressing the Gendered Health Data Gap
The Women’s Health Strategy for England presents an opportunity to ensure that gendered inequalities in health data are recognised and addressed. Caroline Cirado Perez’s ‘Invisible Women’ highlights how women are missing from data sets leading to health interventions and technologies designed for men as the default. For example, women are 50% more likely to be misdiagnosed following a heart attack because participation in clinical trials is generally skewed towards males. In her latest blog, Hanover Health’s Emma Gorton outlines why data should form a key part of the Women’s Health Strategy to help address inequalities in outcomes for women.
Hanover Communications
Greener healthcare - a shared challenge
At six months out from the COP26 UN climate summit in November, political leaders are focusing on industry to help cut emissions. In 2019 the NHS equated to ~5% of total UK carbon footprint, and it is now targeting 2045 net zero for itself and its wider footprint. The search for healthcare suppliers that meet these commitments by the end of the decade is on, and the time to act is now. In the pharmaceutical sector manufacturing sustainable plastic, hydrogen power, or green steel are all being debated – and healthcare companies will need cross-sector support in finding futureproofed solutions. In her latest blog, Hanover Health’s Alison Woodhouse considers the steps and collaboration that will be required in order for the NHS, and UK government, to meet their ambitious net zero targets.
Hanover Communications
Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.
Hanover Communications
COVID-19 has changed the way we must talk about treatment for rare diseases
The turbulence of the last year has brought into sharp focus the difficult choices to be made when it comes to healthcare prioritisation. There is now more of a reluctant acceptance that there will always be someone or something that will miss out so the ‘unjust’ emotional argument won’t resonate in the same way anymore. In her latest blog, Hanover Health’s Emma Gorton considers why in the wake of Covid-19, communicators must change their narrative around the treatment of rare diseases.
Hanover Communications
What does the COVID-19 vaccine mean for the future of R&D?
Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.
Hanover Communications
Is the world ready for a COVID-19 vaccine?
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.
Hanover Communications